SARS-CoV-2 infection Trials in Cincinnati, United States
Conditions / SARS-CoV-2 infection / Cincinnati, United States
Clinical trials for SARS-CoV-2 infection investigate a range of treatment strategies and patient populations.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07300839 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age | RECRUITING | PHASE3 |
| NCT07222384 | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05463068 | Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults | COMPLETED | — |
| NCT04713553 | A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants | COMPLETED | PHASE3 |
| NCT04955626 | To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. | COMPLETED | PHASE3 |
| NCT05172011 | Understanding the Long-term Impact of COVID on Children and Families | ACTIVE_NOT_RECRUITING | — |
| NCT04924660 | Novel Experimental COVID-19 Therapies Affecting Host Response | COMPLETED | PHASE2/PHASE3 |
| NCT05541861 | Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People | COMPLETED | PHASE1 |
| NCT07069309 | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04368728 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | COMPLETED | PHASE2/PHASE3 |